PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. - Wikidata - wikimedia - TriplyDB

PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition.

PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition.

http://www.wikidata.org/entity/Q37445131

about

Cytotoxic and targeted therapy for hereditary cancers Trial watch - inhibiting PARP enzymes for anticancer therapy Clear cell carcinoma of the ovary: molecular insights and future therapeutic perspectives Enhancing tumor-targeting monoclonal antibodies therapy by PARP inhibitors Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer Targeting Breast Cancer Metastasis BRCA1 and estrogen/estrogen receptor in breast cancer: where they interact?Drug Delivery Innovations for Enhancing the Anticancer Potential of Vitamin E Isoforms and Their Derivatives Improving the efficacy of chemoradiation with targeted agents Novel treatment strategies in triple-negative breast cancer: specific role of poly(adenosine diphosphate-ribose) polymerase inhibition Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations.PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions Maximising the potential of AKT inhibitors as anti-cancer treatments Chemoresistance and targeted therapies in ovarian and endometrial cancers The phosphoinositide 3-kinase pathway and therapy resistance in cancer Genome stability pathways in head and neck cancers Targeting PI3K in cancer: impact on tumor cells, their protective stroma, angiogenesis and immunotherapy PI3K and cancer: lessons, challenges and opportunities Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 Genome-wide transcriptome profiling of homologous recombination DNA repair.PARP inhibitors in ovarian cancer: evidence, experience and clinical potential "Back to a false normality": new intriguing mechanisms of resistance to PARP inhibitors Strategies for the Use of Poly(adenosine diphosphate ribose) Polymerase (PARP) Inhibitors in Cancer Therapy.Targeting tumor suppressor networks for cancer therapeutics.Novel drugs that target the estrogen-related receptor alpha: their therapeutic potential in breast cancer Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells.Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.Inhibitors of PARP-1 exert inhibitory effects on the biological characteristics of hepatocellular carcinoma cells in vitro The PARP inhibitors, veliparib and olaparib, are effective chemopreventive agents for delaying mammary tumor development in BRCA1-deficient mice Novel therapeutic strategies in the treatment of triple-negative breast cancer.Base excision repair defects invoke hypersensitivity to PARP inhibition.Definition of PKC-α, CDK6, and MET as therapeutic targets in triple-negative breast cancer The metastatic potential of triple-negative breast cancer is decreased via caloric restriction-mediated reduction of the miR-17~92 cluster The level of Ets-1 protein is regulated by poly(ADP-ribose) polymerase-1 (PARP-1) in cancer cells to prevent DNA damage.A comprehensive evaluation of biomarkers predictive of response to PI3K inhibitors and of resistance mechanisms in head and neck squamous cell carcinoma.Buparlisib , an oral pan-PI3K inhibitor for the treatment of breast cancer.Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?Molecular Heterogeneity of Triple Negative Breast Cancer.The ETS family of oncogenic transcription factors in solid tumours.

P2860

Q26739366-6A7A0903-F68F-4705-A991-9909ABFE536E Q26745673-35331934-B947-4F54-869B-41D1E58B4D24 Q26749280-33E29896-D40F-49D4-97B6-E8B22AF45582 Q26768267-9C6A89AE-39DB-48A7-91D6-31CCB26FCBDA Q26783551-D8B71F4A-73A9-4514-B88D-5DE6F535BE4A Q26783925-55C719A9-74E2-464B-85E8-499BF5C1BCFC Q26822737-B35CEE5F-B6E6-4EE2-9FCC-7BAD21F83A61 Q26824259-3F742A05-1CC7-42B4-8155-6E08BA83EAB6 Q26850193-F31DDC74-FCAF-405C-9E20-A8822DF797CB Q26851765-2491211D-B5DE-4AEE-B349-4DF6AD9A59A5 Q27315948-343B1BA1-6E9D-440F-B1F6-86BEF3E8DBCE Q27853245-7F2C8EBF-07D8-47AC-971C-D4A066F67E64 Q28071345-27F49813-D35F-44D0-AB5B-A326D11A8150 Q28072254-645921BC-E1A4-4B20-88C1-F561D7F69B43 Q28073246-A99E4ECF-E11D-4FBF-A457-08DBF30272E1 Q28082811-A1C8FFEA-CB4F-4B89-9363-52D519EAFA9B Q28391355-1275A35B-D52A-4EB0-ADCD-5CDA42D0F003 Q29248893-19C3A425-8370-4D02-AB3B-0AA8E1EB8727 Q30080017-1E3C31ED-065F-477A-A294-D7AE70902D24 Q30543788-1CFC8116-3D64-4747-9A84-901F1AC2605B Q33598112-F677D9A5-D99E-451D-9AF3-B23A056FC623 Q33605912-F11CF55D-CE43-48B5-BF00-4BB16EA40B42 Q33618910-309020B9-4D3D-4995-9992-CC8C93AD71FC Q33649555-4592D443-5169-4A12-927B-EEB9BE6959D3 Q33657519-37FFC1AE-EA49-45B2-B57C-90D273B25F6F Q33698278-A6606AF7-51CC-4638-9B81-7836E97F3A88 Q33757073-0FE6BAA6-2D05-4E2B-9CC4-DC16BC380E86 Q33769821-11E8D607-C766-4AE0-A82B-09317BDAA44A Q33828196-4E29D2E7-44C2-47E3-B559-54892B4D6E56 Q33874466-CCCF7CBA-0AC1-4553-9D7C-4370529F9FCC Q33887682-7CA950DA-0619-4FA9-A21E-7A868AEEE396 Q34053881-8899A584-1A9E-40CD-B103-C5750C528E19 Q34135362-49551EF8-7279-4621-9B56-2C705B30DD94 Q34150285-20409929-F66F-4BAF-89B4-799CA9C454A4 Q34327567-10712AAF-5BD6-4CD1-A8B4-5F907B6D1825 Q34458117-1DD38005-D21E-44E8-82C4-0F8E9451862A Q34461019-BA0789E4-ECFB-4D56-95AE-4EEF3F021A06 Q34476337-7FE8EC43-4465-40EA-B142-F5F7E855B5D0 Q34533964-15DB19D2-9946-4922-8E4B-E80B56807702 Q34555986-77537759-9971-40C9-A183-0C8F54DEE3B8

P2860

PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition.

http://www.wikidata.org/entity/Q37445131

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 22 August 2012

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

PI3K inhibition impairs BRCA1/ ...... ast cancer to PARP inhibition.

@en

PI3K inhibition impairs BRCA1/ ...... ast cancer to PARP inhibition.

@nl

type

label

PI3K inhibition impairs BRCA1/ ...... ast cancer to PARP inhibition.

@en

PI3K inhibition impairs BRCA1/ ...... ast cancer to PARP inhibition.

@nl

prefLabel

PI3K inhibition impairs BRCA1/ ...... ast cancer to PARP inhibition.

@en

PI3K inhibition impairs BRCA1/ ...... ast cancer to PARP inhibition.

@nl

P1433

Q37445131-00A13F2C-F0D6-4D85-9F73-827BBBE4C2DA

P1476

Q37445131-4028B210-AADF-42FE-A80F-BA06B2DDA64C

P2093

Q37445131-0BC602AF-D72A-4301-900D-9824C0EBCBE0

Q37445131-0FAF2B92-91EC-4DF7-8102-AB736FA7E70C

Q37445131-1B1F279F-D72A-4CC4-BE0A-D03590227F1F

Q37445131-219D273F-C513-407F-A877-D5AF8F50ED79

Q37445131-27495E67-0C7B-43FC-B776-4C8D6C33B8AD

Q37445131-5AB1A706-9C6D-4501-8DCE-16C321AD640B

Q37445131-95E0BE88-0069-4344-8037-F716C6663E9A

Q37445131-971F064B-F934-4219-BFB5-071E564A8EC4

Q37445131-9DA4A5F4-D60A-48B4-AFEE-F1F1C4DEF653

Q37445131-9E0011F9-49BB-4FAF-BD12-4AE4AD221614

P2860

Q37445131-239F3D26-AB01-450A-8B17-FE221F2BF802

Q37445131-2C740133-221D-4288-A255-AF5EAC5E2620

Q37445131-2F2E8D24-685D-4062-A7B2-4B8BA3BBBCA7

Q37445131-3AD80E29-4B88-4B0C-A9B3-C7528280F432

Q37445131-40F7FD39-F17C-4058-A195-D13FAB21737B

Q37445131-42BABC25-17C1-4F26-B09D-039503E37477

Q37445131-4391253F-AFB8-453A-BCDD-85B752745F7E

Q37445131-4720C563-C6D1-4709-8EBD-AEF7F245A2D3

Q37445131-48B55947-6F13-47C9-AE2D-23B859FCE740

Q37445131-53DD1136-E4A1-40FD-888E-B672BEBA44ED

P304

Q37445131-FC920457-C55A-4987-A30E-C3FFD8A00B58

P31

Q37445131-BE666794-488B-475F-8A0E-B1277E8561AD

P356

Q37445131-6F860ADD-C20D-4416-9ABC-9AEC11E5E50B

P433

Q37445131-E6CC24FF-76F7-47A3-AC87-F9AD81245C80

P478

Q37445131-1F4D6947-CDEF-4B73-9A6A-A972B9AF7534

P50

Q37445131-0C49941C-5C05-433B-96BE-55436F51B11E

Q37445131-1A617337-9D36-474D-99B7-66C6BD7FD99D

Q37445131-7D433FAB-C7F1-49D1-8B7B-D8C3705A5994

Q37445131-A2D26371-B734-43FA-BA0F-3F9E6C658211

P577

Q37445131-F846BD0C-D420-4595-980B-BC67B9722F32

P698

Q37445131-8186330F-40C8-45E6-994C-B82A98587536

P921

Q37445131-2FC345E1-F90F-4172-B1A9-48FBC4CAC6AE

P932

Q37445131-58160BC7-4BC0-449E-AE38-94329F1D42F7

P356

2159-8290.CD-11-0348

P1433

Cancer Discovery

P1476

PI3K inhibition impairs BRCA1/ ...... ast cancer to PARP inhibition.

@en

P2093

Celina García-García

http://www.w3.org/2001/XMLSchema#string

Claudia Aura

http://www.w3.org/2001/XMLSchema#string

Isabel T Rubio

http://www.w3.org/2001/XMLSchema#string

Jordi Rodón

http://www.w3.org/2001/XMLSchema#string

José Baselga

http://www.w3.org/2001/XMLSchema#string

José Pérez

http://www.w3.org/2001/XMLSchema#string

Judit Grueso

http://www.w3.org/2001/XMLSchema#string

Kristine Torres-Lockhart

http://www.w3.org/2001/XMLSchema#string

Lei He

http://www.w3.org/2001/XMLSchema#string

Leif W Ellisen

http://www.w3.org/2001/XMLSchema#string

P2860

Ets-2 and components of mammalian SWI/SNF form a repressor complex that negatively regulates the BRCA1 promoter

Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer

Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes

Targeting the PI3K signaling pathway in cancer

HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Initiation of DNA fragmentation during apoptosis induces phosphorylation of H2AX histone at serine 139

ATM phosphorylates histone H2AX in response to DNA double-strand breaks

P304

1036-1047

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/2159-8290.CD-11-0348

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-08-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22915752

http://www.w3.org/2001/XMLSchema#string

P921

P932

5125254

http://www.w3.org/2001/XMLSchema#string